Spyros Papapetropoulos MD, PhD

He was involved in groundbreaking research that led to characterization of genetic forms of
Parkinson’s disease and development of methodologies that revolutionized the
quantification of neuromotor function in clinical research settings. He has authored more
than 165 peer-reviewed publications, several patents, book chapters, presented and
chaired meetings since 1998. Spyros has received awards and has served as a member of
various US government and non-profit committees on healthcare and biomedical research
innovation.

Spyros is an experienced biopharmaceutical executive, a recognized neuroscientist, a
neurodegenerative disease clinician and a change agent. He has held positions of
increasing responsibility at academic institutions as well as small, medium and large
neuroscience-focused biopharma companies. Currently, he is the Chief Development
Officer and member of the Executive Management Team of Acadia Pharmaceuticals and
prior to that he served as Chief Executive Officer and Member of the Board of Directors of
an innovative gene therapy company (SwanBio Therapeutics). He was Head of Research
and Development and Chief Medical Officer at Cavion Inc where he successfully
spearheaded the development of small molecules in novel CNS indications using an
innovative precision medicine platform approach that led to the acquisition of Cavion by
Jazz pharmaceuticals. He also held senior/executive positions at Biogen, Allergan, Pfizer,
and TEVA.

Dr. Papapetropoulos has overseen a broad spectrum of pharmaceutical development
programs leading to successful regulatory filings (>20 INDs/3 NDAs/2 BLAs) and 3 drug
product launches worldwide. For the past 17 years, he has led efforts in academic research,
digital medicine, biopharmaceutical innovation and machine learning developing standards,
novel technology-based tools, and pioneering decentralized clinical trials. He has a track
record on building focused, innovative, fast-paced teams with an emphasis on data, science
and culture.